Intratumoral cancer therapy market set to grow sharply through 2033

The global market for intratumoral cancer therapies is set for a long growth runway, according to new sector analysis from DataM Intelligence, outlining rising clinical use of oncolytic viruses, adenoviral vectors, and localized immunomodulators.

The category grew from about $246 million in 2024 and is forecast to reach roughly $631 million by 2033 as precision immuno-oncology gains traction.

Adoption is strongest in the USA, which contributed an estimated $118 million in 2024, underpinned by more than 38 active trials and increased regulatory designations from the US Food and Drug Administration. Japan also reported rising use, supported by a maturing precision-oncology framework and greater reliance on injectable immunotherapies for hard-to-treat solid tumors.